ANTINEOPLASTIC ACTIVITY;
BLOOD TOXICITY;
BODY SURFACE;
BREAST CANCER;
CANCER SURVIVAL;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
DISEASE SEVERITY;
DOSE CALCULATION;
DOSE RESPONSE;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG MEGADOSE;
DRUG TOLERABILITY;
FEASIBILITY STUDY;
HUMAN;
INTERMETHOD COMPARISON;
LUNG NON SMALL CELL CANCER;
NEUTROPENIA;
OPTIMAL DRUG DOSE;
PREDICTION;
PRIORITY JOURNAL;
REVIEW;
SURVIVAL RATE;
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma
Mayers C et al. (2001) Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91: 2246-2257
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials
Di Maio M et al. (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials. Lancet Oncol 6: 669-677
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients
Scandinavian Breast Group, Study SBG 9401
Bergh J et al. (1998) Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401. Ann Oncol 9: 403-411
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study
Bergh J et al. (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet 356: 1384-1391